Nordea Investment Management AB Acquires 573 Shares of Agios Pharmaceuticals, Inc. $AGIO

Nordea Investment Management AB raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 0.3% during the second quarter, Holdings Channel.com reports. The fund owned 224,746 shares of the biopharmaceutical company’s stock after buying an additional 573 shares during the period. Nordea Investment Management AB’s holdings in Agios Pharmaceuticals were worth $7,520,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Erste Asset Management GmbH grew its position in shares of Agios Pharmaceuticals by 10.9% during the first quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company’s stock valued at $65,439,000 after purchasing an additional 220,000 shares in the last quarter. GW&K Investment Management LLC grew its position in shares of Agios Pharmaceuticals by 19.6% during the first quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock valued at $23,954,000 after purchasing an additional 134,063 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Agios Pharmaceuticals by 145.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company’s stock valued at $21,770,000 after purchasing an additional 440,000 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after purchasing an additional 91,482 shares in the last quarter. Finally, SCS Capital Management LLC purchased a new position in Agios Pharmaceuticals in the first quarter worth about $17,905,000.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AGIO shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, October 8th. Bank of America dropped their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Zacks Research lowered Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Finally, Scotiabank dropped their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $57.25.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $42.65 on Tuesday. The company has a 50 day moving average price of $38.51 and a 200-day moving average price of $34.77. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The company has a market capitalization of $2.48 billion, a PE ratio of 3.88 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Theodore James Jr. Washburn sold 8,546 shares of the company’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $36.87, for a total transaction of $315,091.02. Following the completion of the sale, the insider owned 868 shares in the company, valued at $32,003.16. This represents a 90.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian Goff sold 11,085 shares of the company’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $36.67, for a total value of $406,486.95. Following the transaction, the chief executive officer directly owned 123,528 shares in the company, valued at approximately $4,529,771.76. The trade was a 8.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,482 shares of company stock worth $864,025 over the last 90 days. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.